CN110236182A - A kind of alginate salt complex conjunction ferment of radiation protection prevention and treatment asthenopia - Google Patents
A kind of alginate salt complex conjunction ferment of radiation protection prevention and treatment asthenopia Download PDFInfo
- Publication number
- CN110236182A CN110236182A CN201810192465.XA CN201810192465A CN110236182A CN 110236182 A CN110236182 A CN 110236182A CN 201810192465 A CN201810192465 A CN 201810192465A CN 110236182 A CN110236182 A CN 110236182A
- Authority
- CN
- China
- Prior art keywords
- ferment
- asthenopia
- prevention
- treatment
- radiation protection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002265 prevention Effects 0.000 title claims abstract description 27
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 24
- 230000005855 radiation Effects 0.000 title claims abstract description 15
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 241000195493 Cryptophyta Species 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 12
- 239000000419 plant extract Substances 0.000 claims abstract description 12
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000011669 selenium Substances 0.000 claims abstract description 10
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000011701 zinc Substances 0.000 claims abstract description 9
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 7
- 239000011651 chromium Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 18
- 229910052742 iron Inorganic materials 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 238000005498 polishing Methods 0.000 claims description 8
- 235000011347 Moringa oleifera Nutrition 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 241001474374 Blennius Species 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 2
- 150000002505 iron Chemical class 0.000 claims description 2
- 229910001220 stainless steel Inorganic materials 0.000 claims description 2
- 239000010935 stainless steel Substances 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims description 2
- 241000220215 Moringa Species 0.000 claims 2
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000004438 eyesight Effects 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract description 2
- 239000010703 silicon Substances 0.000 abstract description 2
- 229910052710 silicon Inorganic materials 0.000 abstract description 2
- 230000007423 decrease Effects 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 description 5
- 244000179886 Moringa oleifera Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 241001025261 Neoraja caerulea Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000003471 anti-radiation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000195633 Dunaliella salina Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- WGPCGCOKHWGKJJ-UHFFFAOYSA-N sulfanylidenezinc Chemical compound [Zn]=S WGPCGCOKHWGKJJ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses the formulas of " a kind of alginate salt complex conjunction ferment of radiation protection prevention and treatment asthenopia " and preparation method thereof.Belong to radiation protection prevention and treatment asthenopia field.The present invention be by salt algae, plant extracts, marine extracts, selenium, zinc, chromium, silicon biological element, what water was composed；Selected raw material is food-grade and pharmaceutical grade.Now, eyesight is caused to be gradually reduced because long-time causes the asthenopia of people using mobile phone, computer, it is then as blind as a bat.Above harm is all since asthenopia.Although all very single, effect is also very unsatisfactory currently, there are many various prevention and treatment asthenopia products in market, especially decline aspect year by year in student eyesight.In view of the above problems with the demand of people.The present invention has prevention and treatment radiation, prevention and treatment asthenopia, the preferable function of therapeutic effect and effect.It is mainly used for especially often playing the children and student of mobile phone for a long time using the crowd of mobile phone, computer.
Description
Technical field
The present invention relates to " a kind of alginate salt complex conjunction ferment of radiation protection prevention and treatment asthenopia " and preparation method thereof, belong to anti-spoke
Penetrate prevention and treatment asthenopia field.
Background technique
Now, the asthenopia of people is caused using mobile phone, computer because of long-time, some is because of mobile phone blue ray radiation eyes
Blindness, scientists find that blue light also can be different because of the age to the extent of injury of eyes, are within 6-19 years old 80-90%, 20-39 years old
It is 60-70%, 40-60 years old is 50%." University of Virginia Clinical Ophthalmology expert indicates that the damage of blue ray radiation is one
A chain reaction first causes photaesthesia cell death, then macula retinae lesion is caused then eyesight to be caused to be gradually reduced, then
It is as blind as a bat." more than harm, be all since asthenopia.Although the various prevention and treatment asthenopia products of market today are very
It is more, but it is all very single, and effect is also very unsatisfactory, and there are also different side effects for some.In view of the above problems and market
Demand, the invention discloses one kind not only had no toxic side effect, but also can radiation protection, more can prevent and treat asthenopia its effect again it is good
" a kind of alginate salt complex conjunction ferment of radiation protection prevention and treatment asthenopia " and preparation method thereof.
Summary of the invention
The purpose of the present invention is to provide " a kind of alginate salt complex conjunction ferment of radiation protection prevention and treatment asthenopia " and its production sides
Method.The raw material that the present invention selects is food-grade and pharmaceutical grade entirely, meets the related security regulations of country；It is of the present invention effective
Component materials composition are as follows: salt algae, plant extracts, marine extracts, selenium, zinc, chromium, silicon biological element, water；It, which is formed, is rich in β-
Carrotene and a variety of carotenoid and linoleic acid, lecithin, flavones, folic acid, vitamin E, polysaccharide from Dunaliella salina, dietary fiber,
Vitamin A, B, B1, B2, B3, C, E, glycan glue, high protein and selenium, zinc, calcium, magnesium, phosphorus, potassium, sodium, sulphur, copper, iron, manganese, iodine,
More than the 70 kinds of needed by human body minerals such as fluorine and microelement, in addition there are lysines, tryptophan, phenylalanine, threonine, different bright
18 kinds of amino acid such as propylhomoserin；Its effect can be white interior with radiation protection, prevention and treatment asthenopia and macula retinae disease, prevention and treatment with effect
Barrier improves eyesight, has preferable therapeutic effect for eye disease.
The weight percent of active ingredient raw materials of the present invention forms are as follows:
1, salt algae 5-10%, plant extracts 55-70%, marine extracts 15-20%, biological element 0.01%-
0.3% water polishing 100%；The optimum weight percentage composition of active ingredient raw materials are as follows: salt algae 7%, plant extracts 60%, ocean
Extract 17%, biological element (selenium 60ug/d zinc 10mg/d, chromium 60ug/d, iron 10mg/d, extremely by beta carotene polishing
0.1%), water polishing 100%,
2, plant extracts system moringa enzyme and Golden flower ferment, two ratios are 2: 8, i.e. moringa enzyme: Golden flower ferment
=2: 8
3, marine extracts system seaweed ferment, algal polysaccharides are optional a kind of or two kinds,
4, the selenium in biological element, zinc, chromium, iron series organic salt.
The beneficial effect of raw material of the present invention is with effect:
One, the effect of salt algae with effect:
1, the salt algae element is the anti-cancer substance salt algae of current International Cancer Research Center and american cancer research institute first choice,
2, cataract is assisted in the treatment of, prevention dry eyes, prevention and treatment asthenopia, China TCM Academy of Sciences Xiyuan Hospital, which is delivered, to be ground
Study carefully report " prevention of salt algae element and eyes macular degeneration ", the clinical datas such as " prevention of salt algae element and cataract " show: salt
Algae element can significantly improve body disease-resistant, it is immune and anti-oxidant, prevention and treatment cataract, improve eyesight, to yctalopia, scheroma have compared with
Good therapeutic effect.
Two, should " plant extracts " based on moringa enzyme and Golden flower ferment, rich in vitamin A, B, B1, B2, B3,
C, E, glycan glue, high protein, high microsteping and calcium, magnesium, phosphorus, potassium, sodium, sulphur zinc, copper, iron, manganese, selenium, flavones and a kind of ten amino
Acid contains protein, about the 2 of milk times in the plant material of every 100g；Containing vitamin C, about the 7 of orange times；It is given birth to containing dimension
Plain A, about the 4 of carrot times；Iron content is about 3 times of spinach；Calcic is about 4 times of milk；VE content be higher by 2000 times of milk,
3000 times of fresh orange-juice；Ginkgo and soybean tens are higher by again containing 3 times that potassium is about banana containing flavones.Above-mentioned plant extracts is claimed
Are as follows: " it is a kind of perfect plant enzyme, has significantly to prevention dry eyes, prevention and treatment asthenopia, prevention and treatment cataract, improvement eyesight
Effect；There is remarkable result to diabetes, hypertension, the treatment of cancer and prevention and treatment；" has and eat medicinal, healthcare function enhancing people
Body immunity and emergency power, delay cardiovascular and cerebrovascular aging, antiatherosclerosis, blood pressure lowering, reducing blood viscosity；To coronary heart disease, brain
Thrombus, cerebral hemorrhage, apoplexy and sequelae have apparent preventive and therapeutic effect；" there is magical protective effect to organism, effectively
Protected protein matter molecule invariance inactivation, thus the life process and biological characteristic of the body that sustains life "；" has and remove excessively certainly
By the effect of base and anti peroxidation of lipid, there is antiviral and antitumor, anti-mutation, anti-radiation, antibacterial, anti-inflammatory effect, with mineral
The complexing of element ".
Three, the function and effect of " marine extracts " are somebody's turn to do
" marine extracts " based on seaweed ferment, algal polysaccharides, the high-quality water solubility easily digested and assimilated containing human body
Albumen, the required 8 kinds of amino acid of contained 18 kinds of amino acid and human body institute, absorptivity are up to 90-95%；It is raw containing natural dimension abundant
Element can meet a variety of important vitamins of human life activity's needs, be that B12 containing natural vitamin so far contains in the world
The most abundant plant is measured, and is rich in VitB1, VitB2, VitB6, VitC, VitE, beta carotene, niacin, folic acid, pantothenic acid
The substance beneficial etc. a variety of pairs of human bodies；Containing minerals abundant, wherein the content of iron is 20 times of general iron content food, for biology
Complexing iron easily by human consumption, absorption, and plays a significant role the generation of red blood cell, also containing the work to strengthen muscles and bones
Property calcium and improve the activated carbon of myoneural, the content of selenium and zinc is also very high；Containing unsaturated lipid necessary to natural human body
Fat acid ----γ --- linolenic acid (GLA), 22 carbon, 6 olefin(e) acid (DHA)；Containing can promote the beta carotene of immune function of human body, contain
It enriches blood natural ferroheme the resource --- --- chlorophyll of hematopoiesis；Containing huge energy sink --- polysaccharide can prevent dry eyes
Disease, prevention and treatment cataract, improves eyesight at prevention and treatment asthenopia.
Four, the function and effect of the selenium in the biological element, zinc, chromium, iron
The biological element keeps balance in the different tissue of body, it is ensured that cell function is normal and healthy；If this is balanced
It is created disturbances to, abnormal situation will occur, cause disease.The biological element is the activator of a variety of enzymes, is also played anti-
Radiation, prevents and treats the effect of asthenopia.
Five, it is of the invention it is specific the production method is as follows:
Specific embodiment
1, it is spare to weigh salt algae 7%
2, it is spare to weigh plant extracts 60%, moringa enzyme and Golden flower ferment, two ratios are 2: 8
3, it is spare to weigh marine extracts (seaweed ferment) 17%
4, it is spare to weigh biological element 0.1%
5, the spare polishing 100% of water is weighed,
6,30-50min in " 4 " addition " 2 ", is stirred, 30-40 DEG C, revolving speed 30-50 turns,
7,30-50min in " 1 " addition " 6 ", is stirred, 25-30 DEG C, revolving speed 30-50 turns,
8,30-50min in " 3 " addition " 7 ", is stirred, 25-30 DEG C, revolving speed 30-50 turns,
9,30-50min in " 5 " addition " 8 ", is stirred, 20-25 DEG C, revolving speed 30-50 turns,
10, " 9 " static ageing 3-10 days, filtrate is taken, is aged 30-60 days, the salt of asthenopia is both prevented and treated for radiation protection
Algae composite enzyme,
11, the above capital equipment is the reaction kettle of stainless steel automatic temperature-control, speed regulation.
Claims (4)
- A kind of weight percent composition of the active ingredient raw materials of " 1. alginate salt complex conjunction ferment of radiation protection prevention and treatment asthenopia " are as follows:Salt algae 5-10%, plant extracts 55-70%, marine extracts 15-20%, biological element 0.01%-0.3%, water are mended Neat 100%.
- 2. as described in claim 1, the optimum weight percentage composition of active ingredient raw materials are as follows: salt algae 7%, plant extracts 60%, marine extracts 17%, biological element 0.1% (selenium 60ug/d zinc 10mg/d, chromium 60ug/d, iron 10mg/d, by β-Hu Luo Bu Su polishing is to 0.1%), water polishing 100%.
- 3. plant extracts system moringa enzyme and Golden flower ferment as described in claim 1,2, two ratios are 2: 8, i.e. Moringa ferment Element: Golden flower ferment=2: 8；Marine extracts system seaweed ferment, algal polysaccharides are optional a kind of or two kinds.
- 4. as described in claim 1,2, selenium, zinc, chromium, iron series organic salt in biological element,Specific embodiment1, it is spare to weigh salt algae 7%,2, it is spare to weigh plant extracts 60%,3, it is spare to weigh marine extracts (seaweed ferment) 17%4, weigh biological element 0.1% it is spare,5, the spare polishing 100% of water water is weighed,6,30-50min in " 4 " addition " 2 ", is stirred, 30-40 DEG C, revolving speed 30-50 turns,7,30-50min in " 1 " addition " 6 ", is stirred, 25-30 DEG C, revolving speed 30-50 turns,8,30-50min in " 3 " addition " 7 ", is stirred, 25-30 DEG C, revolving speed 30-50 turns,9, in " 5 " addition " 8 ", polishing 100% stirs 30-50min, and 20-25 DEG C, revolving speed 30-50 turns,10, " 9 " static ageing 3-10 days, filtrate is taken, is aged 30-60 days, the as alginate salt complex of radiation protection prevention and treatment asthenopia Ferment is closed,11, the above capital equipment is the reaction kettle of stainless steel automatic temperature-control, speed regulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810192465.XA CN110236182A (en) | 2018-03-09 | 2018-03-09 | A kind of alginate salt complex conjunction ferment of radiation protection prevention and treatment asthenopia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810192465.XA CN110236182A (en) | 2018-03-09 | 2018-03-09 | A kind of alginate salt complex conjunction ferment of radiation protection prevention and treatment asthenopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110236182A true CN110236182A (en) | 2019-09-17 |
Family
ID=67882751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810192465.XA Pending CN110236182A (en) | 2018-03-09 | 2018-03-09 | A kind of alginate salt complex conjunction ferment of radiation protection prevention and treatment asthenopia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110236182A (en) |
-
2018
- 2018-03-09 CN CN201810192465.XA patent/CN110236182A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7887847B2 (en) | Nutritional supplement for treatment of ocular diseases | |
| US8389028B2 (en) | Method for promoting eye health | |
| CN102919383A (en) | Blend oil containing peony seed oil and preparation method of blend oil | |
| CN102318742B (en) | Antioxidant health care egg production method and composite antioxidant used by same | |
| JP2009523127A (en) | Compositions and methods for inhibiting the progression of macular degeneration and improving healthy vision | |
| EP2023945A2 (en) | Composition for improving eye health | |
| Kale et al. | Role of antioxidants and nutrition in oxidative stress: a review | |
| Rafeeq et al. | Biochemistry of fat soluble vitamins, sources, biochemical functions and toxicity | |
| US20160151437A1 (en) | Nutritional supplements for improved vision and methods of treating the same | |
| Basheer et al. | Microalgae in human health and medicine | |
| CN103431392B (en) | Composite marine food for special dietary uses for diabetics | |
| Arshad et al. | Functional foods and human health: an overview | |
| CN107712537A (en) | A kind of lutein ester solid beverage | |
| Xiao et al. | Study on functional components of functional food based on food vitamins | |
| RU2489038C1 (en) | Product for dietary, prophylactic and functional alimentation suitable for humans suffering from chronic cerebral ischemia | |
| US20040254095A1 (en) | Supplement for treating musculoskeletal disorders | |
| CN110236182A (en) | A kind of alginate salt complex conjunction ferment of radiation protection prevention and treatment asthenopia | |
| CN104432392A (en) | Heart-strengthening and aging-resisting blueberry solid particle beverage and preparation method thereof | |
| CN103404875B (en) | Complex ocean special-diet food eaten by patients with cardiovascular disease | |
| US20140087011A1 (en) | RyWhe / The Drink of Life | |
| CN112841490A (en) | Solid beverage with prolonged service life | |
| CN104187668A (en) | Nutritional health care product containing natural astaxanthin | |
| Mir et al. | Extraction of carotenoids from agro-industrial waste | |
| CN111758793A (en) | Lycopene edible oil | |
| Prokisch et al. | Fortification of Functional Foods for Human Health: A Case Study of Honey and Yogurt for Diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190917 |
|
| WD01 | Invention patent application deemed withdrawn after publication |